Europe/Asia USA
Bachem AG Bachem Americas, Inc.
Hauptstrasse 144 3132 Kashiwa Street
4416 Bubendorf - Switzerland Torrance, CA 90505 - USA
Tel +41 61 935 2323 Tel +1 888 422 2436
Fax +41 61 935 2325 +1 888 4BACHEM
E-mail sales.ch@bachem.com +1 310 539 4171
  Fax +1 310 539 9428
  E-mail sales.us@bachem.com

PEPTIDE TRENDS JUNE 2016

MEET US AT THE WEBINAR ON PEPTIDES IN ALZHEIMER'S RESEARCH

Alzheimer‘s disease has become a major health and social problem in the developed countries with an increasing proportion of older people. Individuals suffering from this disease show a gradual loss of cognitive functions and disturbances in behavior. The onset of Alzheimer‘s disease is usually above 60 years and the risk to develop the disease increases with age.

In this webinar we present our amyloid peptides, inhibitors and labelled secretase substrates that are widely used in the research of Alzheimer’s disease. The deposition of amyloid β-peptide (Aβ) in the brain is characteristic for the disease and the resulting plaques mainly consist of Aβ (1-40) and Aβ (1-42). Despite of progresses in the understanding of the pathology of Alzheimer‘s disease, therapeutic strategies still rely on detailed knowledge of the molecules involved. Research covers the enzymatic processing of the amyloid precursor protein as well as the fate of the cleavage products.

To register please click here.

Date: Wednesday, June 22, 2016
Time: 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central)
Duration: 60 minutes
Featured Speaker: Violeta Jordan, Global Director of Product Management, Bachem

ANTIMICROBIAL PEPTIDES

Antimicrobial peptides play an important role in the defense mechanisms of organisms. They also referred to as “host defense peptides” in higher eukaryotic organisms. Antimicrobial peptides are part of the innate immunity. Most of them consist of 5-40 amino acids with a molecular weight of less than 10kDa. They act as natural antibiotics and provide effective defense against infections. But some studies have shown new functions like antineoplastic effects, wound healing, skin regeneration and others. Due to increasing antimicrobial resistance, synthetic as well as natural antimicrobial peptides are interesting alternatives. Antimicrobial peptides interact primarily with microorganisms, showing no toxicity toward mammalian cells. They destroy microorganisms mostly by membrane disruption, making it difficult for microorganisms to develop resistance. Hence, acquired resistance did not become an issue with antimicrobial peptides.

Antimicrobial peptides are classified into four major groups: amphipathic α-helical (dermaseptin, LL-37), β-sheet (defensins), β-hairpin (bactenecin, tachyplesins) and extended antimicrobial peptides (indolicidin, histatins). Generally antimicrobial peptides carry hydrophobic residues and a net positive charge allowing to interact with the negatively charged cell membrane. This interaction with a bacterial membrane leads to leakage of cell contents. Eukaryotic antimicrobial peptides can be categorized into cationic ones: defensins, cathelicidins, cecropins, thionins, amino acid enriched peptides, histones. There are also anionic neuropeptide-derived and aspartic acid-rich peptides. Proposed models for the mechanism of action are the “Barrel-Stave model”, the “Toroidal model” (“Wormhole model”) or the “Carpet model”.

The Barrel-Stave model describes a mechanism in which antimicrobial peptides form a barrel-like pore within the bacterial membrane with the individual antimicrobial peptides or their complexes being the staves. Arranged in this manner, the hydrophobic regions of the antimicrobial peptides point outwards towards the acyl chains of the membrane whereas the hydrophilic areas form the pore. This model is proposed e.g. for dermcidin. The pores described by the Toroidal Pore model differ from those of the Barrel-Stave model. Primarily, the outer and inner leaflets of the membrane are not intercalated in the transmembrane channel. This model is proposed for LL-37. A different mechanism is proposed in the Carpet model where antimicrobial peptides first cover the outer surface of the membrane and then disrupt the membrane like detergents by forming micelle-like units. Certain antimicrobial peptides penetrate the bacterial membrane without channel formation. They act on intracellular targets by e.g. inhibiting nucleic acid and/or protein synthesis. This model is proposed for piscidins.

Apart from therapeutic usage, research is also going to employing antimicrobial peptides as surface active molecules, e.g. attaching them to the surface of implantable medical devices to reduce biofilm formation. A challenge here is to reach sufficient surface concentrations of the peptides. Binding of antimicrobial peptides to a Silicon Foley catheter reduced the biofilm formation by pathogens causing urinary tract infection. For diagnostics purpose, synthetic antimicrobial peptides designed with highly specific targeting and binding capabilities were immobilized onto a microsensor array. This allowed rapid and multiplexed detection of bacterial pathogens. Linking antimicrobial peptides to nanoparticles leads to site specific targeting and delivery of drug molecules. Dermaseptin entrapped in chitosan nanoparticles has shown to be slightly more active against tumor cells than the free peptide.

For more information please refer to Bachem’s monograph on antimicrobial peptides which can be downloaded here. Bachem also offers a large portfolio of antimicrobial peptides and related compounds (shop.bachem.com).

 

 

 

References:

Bachem monograph Antimicrobial Peptides, 2008870 published by Global Marketing, Bachem Group (2016)
G. Wang et al., Antimicrobial peptides in 2014, Pharmaceuticals 8, 123-150 (2015)
J.P. da Costa et al., Antimicrobial peptides: an alternative for innovative medicines? Appl Microbiol Biotechnol 99, 2023-40 (2015)
B. E. Oyinloye, Reactive oxygen species, apoptosis, antimicrobial peptides and human inflammatory diseases, Pharmaceuticals 8, 151-175 (2015)

ANTIMICROBIAL PEPTIDES IN CLINICAL DEVELOPMENT

Drug resistant-bacteria are estimated to cause 25000 deaths and cost more than 1.5 billion USD each year in healthcare related expenses and productivity losses in the European Union alone (1). Hence, drug-resistant infections are a serious global health problem and there is an urgent need for novel antimicrobials. Antimicrobial peptides (AMPs) are of interest as potential therapeutics as broad-spectrum antibiotics for various microorganisms. AMPs have the ability to avoid antimicrobial resistance in many cases.

More than 5000 AMPs have been discovered or synthesized to date (2) and several companies have AMPs in various stages of active development, from preclinical studies to Phase III. A selection of AMPs in active clinical development is highlighted in Table 1 below.

 

 

Product Name

Active Ingredient

Companies Involved

Highest Phase

Condition Treated

Locilex®

pexiganan acetate

Abeona Therapeutics Inc, SmithKline Beecham Plc,
RRD International LLC, GlaxoSmithKline plc,
Dipexium Pharmaceuticals Inc

III

Diabetic Foot Ulcer(III)
Skin Infections(I)

CLS001

omiganan pentahydrochloride

Cadence Pharmaceuticals Inc, Fujisawa Pharmaceutical Co., Ltd., Cutanea Life Sciences, Biowest Therapeutics Inc.,
Maruho Co Ltd

 III

Papulopustular Rosacea(III)
Acne Vulgaris(II)
Atopic Dermatitis(II)
Dermatology(II)

MK4261

surotomycin

Cubist Pharmaceuticals Inc,
Merck & Co Inc

 III

Clostridium Difficile Associated Diarrhea(III)

TD1792

--

Innoviva, Theravance Biopharma U.S Inc, R-Pharm

 III

Skin Bacterial Infections(III)
Pneumonia(I)

C16G2

--

UCLA School of Dentistry, Chengdu Sen Nuo Wei Biotechnology Co Ltd, C3 Jian Inc

 II

Dental Caries(II)

DPK060

--

DermaGen AB, Pergamum AB

 II

Atopic Dermatitis(II)
Otitis Externa(II)

LL37

--

Pergamum AB

 II

Varicose Ulcer(II)

LytixarTM

LTX109

Lytix Biopharma AS

 II

Impetigo(II)
Staphylococcal Infections(II)

Novexatin®

--

NovaBiotics Ltd

 II

Tinea Unguium(II)

POL7080

--

Polyphor Ltd, Roche

 II

Pseudomonas Infections(II)

SGX942

dusquetide

Inimex Pharmaceuticals Inc, SciClone Pharmaceuticals Inc, Soligenix Inc

 II

Therapy Induced Side-effects(II)
Bacterial Infections(I)
Immunology and Inflammation(PC)
Skin Bacterial Infections(PC)
Ulcerative Colitis(PC)

NVB302

--

Novacta Biosystems Limited

 I

Clostridium Difficile Infections(I)

Table 1: AMPs in Active Phase I to Phase III Development and Pending Approval (3), (4)

Phase III Clinical Candidates
Locilex® (pexiganan acetate) is a synthetic 22-amino acid peptide originally isolated from the skin of the African Clawed Frog. Locilex has demonstrated bactericidal activity against gram-positive, gram negative, aerobic, anerobic and resistant bacteria (4). This AMP acts by altering bacterial cell membrane permeability. Dipexium Pharmaceuticals is currently conducting two pivotal Phase III clinical trials of Locilex in mild diabetic foot ulcers and the company plans to file a New Drug Application (NDA) and Marketing Authorization Application (MAA) for Locilex in 2017 (5).

Cutanea Life Sciences is developing CLS001 (omiganan pentahydrochloride), an antibiotic and antimicrobial cationic peptide, for rosacea and other indications. In 2015, Cutanea Life Sciences initiated a Phase III study to evaluate the safety and efficacy of once-daily CLS001 topical gel versus vehicle administered in patients with papulopustual rosacea (3).

Cubist Pharmaceuticals, a subsidiary of Merck & Co, is developing MK4261 (surotomycin) for the treatment of Clostridium difficile associated diarrhea (CDAD). Surotomycin is a lipopeptide that exhibits potent and rapid bactericidal activity. In 2015, Cubist announced the completion of a Phase III study of surotomycin in patients with CDAD (3).

TD1792 is a synthetic glycopeptide-cephalosporin heterodimer which is designed to combine the antibacterial activities of its glycopeptide and beta-lactam components. Theravance Biopharma has partnered with R-Pharm to develop TD1792 as a treatment for infections caused by gram-positive infections. Theravance has completed a Phase II proof-of-concept study of TD1792 and R-Pharm has initiated a Phase III study of TD1792 in complicated skin and soft tissue infections caused by gram-positive bacteria (3).

Conclusion
The urgent need to develop new antimicrobials has been driving AMP research and clinical candidates forward. Further AMPs may enter clinical trials in the future as several preclinical candidates are in the pipeline. To support researchers and organizations working in the area of AMPs, Bachem offers a wide variety of AMP catalog peptides, comprehensive custom peptide synthesis services and production of peptide-based New Chemical Entities.
For further reading we recommend our AMP brochure, which is available for you as pdf download in our technical library here.

 

References:
(1) World Health Organization. Antibiotic Resistance. World Health Organization. [Online] October 2015. [Cited: April 29, 2016.] http://www.who.int/mediacentre/factsheets/antibiotic-resistance/en/
(2) Bahar, AA and Ren D. Antimicrobial Peptides. Pharmaceuticals. Dec 2013, Vol. 6, 12, pp. 1543-1575.
(3) Medtrack. [Online] [Cited: May 2, 2016.]
(4) Locilex. Dipexium Pharmaceuticals. [Online] 2016. [Cited: May 6, 2016.] http://www.dipexiumpharmaceuticals.com/locilex/overview
(5) Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials. Dipexium Pharmaceuticals. [Online] February 4, 2016. [Cited: May 9, 2016.] http://ir.dipexiumpharmaceuticals.com/press-releases/detail/205/dipexium-pharmaceuticals-reaches-75-enrollment-milestone

 

MEET BACHEM: PETE NGUYEN, TECHNICAL SALES MANAGER

PT: What is your official job title at Bachem?
Pete: My official title is Technical Sales Manager.

PT: How long have you been with Bachem?
Pete: I have worked at Bachem for one and a half year. I worked at Baxter Biosciences before joining Bachem.

PT: Briefly, what do you do at Bachem?
Pete: I lead the effort in sales of research grade custom synthesis products in the US, Canada and Latin America.

PT: What is your academic background?
Pete: I am a Ph. D. biochemist by training.

PT: What do you like to do outside of work?
Pete: I love to travel and try different cuisines around the world.

PT: What do you like most about your job?
Pete: Every date at work is different. Every project that I work on is unique where we will be able to offer a tailored package to our customers’ need. The chance to continue meeting new customers and learn about new researches makes it always exciting.

PT: Thank you very much Pete.

Peptide Highlights

Interesting news about peptides in basic research and pharmaceutical development:

Pittsburgh scientists quell virus-bacteria infections with engineered antimicrobial drug-FierceBiotech
Peptide payload-UC Santa Barbara
Cell-penetrating peptide delivers drugs on a molecular level-ScienceDaily

Literature Citations

Bachem peptides and biochemicals are widely cited in research publications. Congratulations to all our customers with recent publications!

Marten Villmow, Monika Baumann, Miroslav Malesevic, Rolf Sachs, Gerd Hause, Marcus Fändrich, Jochen Balbach, and Cordelia Schiene-Fischer
Inhibition of Aβ(1–40) fibril formation by cyclophilins
Biochem. J. 2016; May 2016; 473:1355-1368.
http://www.biochemj.org/content/473/10/1355

Jae-Pyo Jeon, Dhananjay P. Thakur, Jin-bin Tian, Insuk So, and Michael X. Zhu
Regulator of G-protein signalling and GoLoco proteins suppress TRPC4 channel function via acting at Gαi/o
Biochem. J. 2016; May 2016; 473:1379-1390. 
http://www.biochemj.org/content/473/10/1379

Rachel R. Deer and John N. Stallone
Effects of estrogen on cerebrovascular function: age-dependent shifts from beneficial to detrimental in small cerebral arteries of the rat
Am J Physiol Heart Circ Physiol, May 2016; 310: H1285 - H1294.
http://ajpheart.physiology.org/content/310/10/H1285

Nitin Kumar, Pablo Nakagawa, Branislava Janic, Cesar A. Romero, Morel E. Worou, Sumit R. Monu, Edward L. Peterson, Jiajiu Shaw, Frederick Valeriote, Elimelda M. Ongeri, Jean-Marie V. Niyitegeka, Nour-Eddine Rhaleb, and Oscar A. Carretero
The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase
Am J Physiol Renal Physiol, May 2016; 310: F1026 - F1034.
http://ajprenal.physiology.org/content/310/10/F1026

Jill S. Carmody, Rodrigo Muñoz, Huali Yin, and Lee M. Kaplan
Peripheral, but not central, GLP-1 receptor signaling is required for improvement in glucose tolerance after Roux-en-Y gastric bypass in mice
Am J Physiol Endocrinol Metab, May 2016; 310: E855 - E861.
http://ajpendo.physiology.org/content/310/10/E855